shARv7 lentivirus

shARv7 lentivirus is an experimental gene therapy agent designed to silence the expression of the androgen receptor splicing variant 7 (ARv7) through RNA interference. ARv7 is a truncated, constitutively active form of the androgen receptor that is frequently upregulated in metastatic castration-resistant prostate cancer (mCRPC) and is associated with resistance to androgen deprivation therapy (ADT), taxane chemotherapy, and radiotherapy. By delivering a short hairpin RNA (shRNA) via a lentiviral vector, this agent targets the unique cryptic exon 3 (CE3) of the ARv7 mRNA, leading to its degradation. This knockdown inhibits ARv7-mediated DNA damage response (DDR) pathways, including homologous recombination (HR) and non-homologous end joining (NHEJ), thereby sensitizing prostate cancer cells to DNA-damaging agents and PARP inhibitors.

Other names

lentiviral shRNA targeting ARv7ARv7-shRNA lentivirusARv-7-shRNA lentivirusARv 7-shRNA lentivirus